Editor's note: The Shepard Ambellas Show airs LIVE weekdays (Mon-Fri) on the Shepard Ambellas YouTube channel from 5-7 pm Eastern/4C/2P. Subscribe now! Turn notifications on immediately. An archived version of the show is also available on Apple Podcasts, Spotify, Google Podcasts, Castbox, Deezer, Podcast Addict, Podchaser, JioSaavn, and Spreaker for you listening pleasure.
(INTELLIHUB) — One university study shows that more than 50% of people are people willing to pay for an Ebola vaccine after the 2014 West African outbreak was highly publicized by western media causing a contagion scare.
A recent piece published by EurekAlert gives the details:
George Mason University researchers conducted a study during the height of the epidemic and found that a majority of participants (59.7 percent) would pay at least $1 for an Ebola Vaccine. Those who were willing to pay at least $1 had typically traveled internationally in the last 12 months, were interested in getting an Ebola vaccine, and believed that the U.S. government should spend money to control Ebola and assume worldwide leadership in confronting emerging epidemics.
The nationally representative survey of U.S. adults was published in January in Human Vaccines and Immunotherapeutics. It included questions on Ebola-related knowledge, attitudes, and behaviors as well as background information (e.g., demographics, international travel) to test for indicators of willingness to pay for a vaccine.
Dr. Julia Painter, an assistant professor in Mason’s Department of Global and Community Health (GCH) led the study with support from assistant professor Dr. Michael von Fricken; graduate student Suyane Viana de O. Mesquita (now an alumna of the Master of Public Health program); and professor Dr. Ralph J. DiClemente from Emory University.
“We believe this is the first study to assess willingness to pay for an Ebola vaccine in the United States,” Painter explains. “This is important because previous studies conducted in West Africa are not generalizable to the U.S. population. Once developed, a licensed vaccine against Ebola “We were unsure of what to expect. The actual risk of Ebola infection among the general U.S. population was low, which could have led to lack of willingness so spend money on a vaccine. On the other hand, the outbreak garnered extensive media coverage, leading to a national contagion of fear. This fear could have driven people to be willing to pay for a vaccine.”
The professor’s statements are profound and will likely one day become a reality.
Will the powers-that-be release the Ebola virus onto the U.S. populace in order to sell hundreds-of-millions of vaccines?
— Intellihub (@intellihubnews) March 12, 2018
Please take the poll, comment below, and share!
— Aldo Raine (MAGAforce) (@Tabertronic) March 11, 2018